Ono and Aitia Partner to Advance AI Drug Discovery
The collaboration uses Digital Twin technology to identify targets for complex neurological diseases.
A high-tech laboratory featuring a glowing digital twin of a human brain on a transparent screen. Data points and neural pathways are highlighted in blue and white, symbolizing AI-driven neurological research.
Photo: Kronos Digital News
Japan-based Ono Pharmaceutical has partnered with Aitia to accelerate drug discovery for neurological diseases [1]. The collaboration will utilize Aitia’s “Gemini Digital Twin” technology to identify novel therapeutic targets and biomarkers [1][2]. This approach leverages causal AI to analyze complex biological data and simulate disease mechanisms [3].
The partnership aims to address unmet needs in neurology by focusing on discovery efficiency [3]. Ono Pharmaceutical will provide research expertise while Aitia contributes its proprietary AI platform [1]. This multi-year agreement reflects growing industry interest in digital twins for pharmaceutical research [2].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
biospace.com
https://www.biospace.com/press-releases/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases
- 2.↗
jp.ibtimes.com
https://jp.ibtimes.com/ono-pharmaceutical-partners-us-aitia-gemini-digital-twin-discovery-104101
- 3.↗
pharmaceutical-technology.com
https://www.pharmaceutical-technology.com/news/ono-pharmaceutical-aitia-drug-discovery-neurology/
Related stories
View all
About the author
Kronos Digital News Desk covers news and editorial analysis for Kronos Digital News.